Understanding the Nilotinib trials
The results of a Phase II trial on the safety of nilotinib in people with Parkinson’s has shown ambiguous biochemical results and a greater number of adverse events in the treated groups.
The results of a Phase II trial on the safety of nilotinib in people with Parkinson’s has shown ambiguous biochemical results and a greater number of adverse events in the treated groups.
Regular home-based aerobic exercise appears to reduce the progression of Parkinson’s.
AUDIO VERSION AVAILABLE.
Focus ultrasound (FUS) is a promising new area to improve delivery of drugs and neurotrophic factors
Gene therapy with GDNF: results of US trial.
AUDIO VERSION AVAILABLE
Study without blinding or a placebo arm has shown benefits from NAC.
Two Parkinson’s experts comment on the GDNF trial results.
AUDIO VERSION AVAILABLE.